The Journal of Clinical Psychiatry

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

DISCLAIMER

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1: Comedications taken by the participants

Antidepressants	Benzodiazepines	Lipid-lowering drugs	Antidiabetics	Antihypertensives	Weight-inducing psychotropic drugs
Citalopram	Alprazolam	Atorvastatin	Gliclazide	Amlodipine	Amisulpride
Duloxetine	Bromazepam	Rosuvastatin	Insulin	Bisoprolol	Amitriptyline
Escitalopram	Clobazam	Simvastatin	Insulin aspart	Candesartan	Aripiprazole
Fluoxetine	Clorazepate		Insulin degludec	Diltiazem	Asenapine
Fluvoxamine	Diazepam		Insulin glargine	Enalapril	Chlorprothixene
Moclobemide	Flurazepam		Insulin lispro	Furosemide	Clozapine
Paroxetine	Lorazepam		Liraglutide	Glyceryl trinitrate	Flupentixol
Reboxetine	Lormetazepam		Metformin	Hydrochlorothiazide	Haloperidol
Sertraline	Midazolam		Repaglinide	Indapamide	Levomepromazine
Trazodone	Oxazepam		Sitagliptin	Irbesartan	Lithium
Venlafaxine	Triazolam			Lercanidipine	Lurasidone
				Lisinopril	Mirtazapine
				Losartan	Olanzapine
				Metoprolol	Paliperidone
				Modamide	Pipamperone
				Nifedipine	Quetiapine
				Perindopril	Risperidone
				Spironolactone	Sertindole
				Torasemide	Zuclopenthixol
				Verapamil	

Supplementary Table 2. Logistic regression[a]

Variables	Weight gain ≥ 5% in 1 month			Weight gain ≥ 7% in 1 year		
	Odds ratio	95%CI	P	Odds ratio	95%CI	P
Mean dose[b]	1.49	0.99 to 2.27	0.06	1.21	0.84 to 1.76	0.30
Max dose[b]	1.62	1.11 to 2.41	**0.015**	1.31	0.94 to 1.83	0.12
N patients	196					

[a]*Logistic regression on the occurrence of ≥5%* weight gain *within the first month of treatment and on the development of ≥7% weight gain within the following year. The models were adjusted for age, sex, baseline BMI, smoking status, diagnostic and psychotropic comedication risks.*
[b]*Mean dose (mg/day) reflects the average value of dose received during the first month of treatment (weight gain ≥5%) and within 12 months (weight gain ≥7%), and max dose (mg/day) represents the maximum value.*
Abbreviations: CI: confidence interval, N: number.

Supplementary Figure 1. Flowchart of the selection of patients

Supplementary Figure 2. Scatter plot of the correlation between valproate doses (mg/day) and weight gain (%)

Supplementary Figure 3. Scatter plot of the correlation between valproate doses (mg/day) and weight gain (%), excluding patients who received doses greater than 2000mg/day (N=22, 10% of the cohort)